Suchergebnisse - "Stagno, Fabio"

PubPharm (204)

41

On the road to treatment-free remission in chronic myeloid leukemia : what about 'the others'?

enthalten in: Expert review of anticancer therapy | 2020

von Stagno, F. | Breccia, M. | Di Raimondo, F.

42

Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia

enthalten in: HemaSphere | 2020

von Fontana, D. | Ramazzotti, D. | Aroldi, A. | +27

43

Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation

enthalten in: Blood | 2020

von Diral, E. | Mori, S. | Antolini, L. | +20

44

Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients

enthalten in: Anticancer research | 2020

von Markovic, U. | Bulla, A. | Leotta, S. | +6

45

Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey

enthalten in: Leukemia | 2020

von Breccia, M. | Abruzzese, E. | Bocchia, M. | +50

46

Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors

enthalten in: Annals of hematology | 2020

von Mulas, O. | Caocci, G. | Stagno, F. | +36

47

Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions

enthalten in: Blood cancer discovery | 2020

von Silvestri, G. | Trotta, R. | Stramucci, L. | +35

CommentIn: Blood Cancer Discov. 2020 Jun 22;1(1):13-15. - PMID 34661136

48

Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study

enthalten in: Blood cancer journal | 2020

von Caocci, G. | Mulas, O. | Capodanno, I. | +33

49

Optimal Response in a Patient With CML Expressing BCR-ABL1 E6A2 Fusion Transcript With Nilotinib Therapy : A Case Report

enthalten in: In vivo (Athens, Greece) | 2020

von Manzella, L. | Tirrò, E. | Vitale, S. | +9

50

Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors

enthalten in: Annals of hematology | 2020

von Mulas, O. | Caocci, G. | Stagno, F. | +36